Introduction {#S1}
============

It is estimated that 1.7 million people in the United States, over the age of 12, engage in the non-therapeutic use of methamphetamine (MA)^[@R1]^. Despite the prevalence and untoward consequences of MA use^[@R2]^, there is no FDA-approved medication for MA-use disorder. A better understanding of the associated neurobiological features may help guide the development of treatments.

Positron emission tomography (PET) has revealed dopaminergic abnormalities, including lower dopamine transporter availability (i.e., binding potential, BPND)^[@R3],\ [@R4]^, higher vesicular monoamine transporter BPND^[@R5]^, and lower striatal dopamine D2-type receptor BPND^[@R6],\ [@R7]^, in striata of MA users. Dopamine D1 receptors have been evaluated in MA users only postmortem, showing no differences vs. controls in the caudate nucleus and putamen but higher density in the nucleus accumbens^[@R8]^. In rats, however, administration of a D1 antagonist attenuates cocaine-seeking behavior and behavioral sensitization^[@R9]^, and injection of D1 antagonist into striatum attenuates the MA-induced decrease in monoamine transporter density and cerebral cortical neuronal activity^[@R10],\ [@R11]^. Thus, D1-type receptors may influence the untoward effects of MA.

Activities in the direct and indirect pathways from the striatum adjust the output of the basal ganglia^[@R12]^. D1-type receptors are expressed on direct-pathway striatal neurons projecting to the substantia nigra pars reticulata and the globus pallidus pars interna (SNr/GPi), whereas D2-type receptors are expressed on dendrites of indirect-pathway striatal neurons, projecting to SNr/GPi via the globus pallidus pars externa (GPe) and subthalamic nucleus. The two pathways have inhibitory and excitatory effects, respectively, on SNr/GPi, which provides inhibition to the thalamus, regulating glutamatergic excitatory signals to the cortex. Dopamine enhances activity in D1-type receptor-expressing neurons and inhibits neurons expressing D2-type receptors^[@R13]^.

MA-induced striatal dopamine release can influence cortical function. In rats, intra-striatal injection of either a D1- or D2-type receptor antagonist prevented MA-induced c-Fos protein expression in the cerebral cortex^[@R11]^. In contrast, intrastriatal injection of SKF 38393, a D1-type receptor agonist, increased cortical c-Fos expression, a marker of neuronal activity^[@R14]^, but administration of quinpirole, a D2-type agonist, did not; the increased expression was blocked by systemic administration of SCH23390, a D1-receptor antagonist^[@R15]^.

We compared D1-type BPND in MA-dependent and healthy-control subjects, and tested for associations of striatal BPND of D1- and D2-type receptors with cortical structure. Given prior findings^[@R6]--[@R8]^, we expected MA users not to differ from controls in D1-type BPND despite lower D2-type BPND. Moreover, we considered the fact that MA promotes dopamine efflux, increasing striatal concentrations of synaptic dopamine to levels adequate to stimulate D1 receptors, which have relatively lower affinity for dopamine than D2 receptors ^[@R16]^. Because activation of D1 receptors on medium spiny neurons of the direct pathway inhibits firing of GABAergic basal ganglia output nuclei, thereby disinhibiting thalamocortical circuitry ^[@R17]^, we expected cortical gray-matter thickness to be associated with cumulative MA use and with striatal D1-type BPND in MA users, reflecting adaptation to MA-induced activation.

Methods {#S2}
=======

Participants {#S3}
------------

All procedures were approved by the Institution Review Boards of the University of California Los Angeles and the Greater Los Angeles Veterans Affairs Health Care System. Participants (23 control; 21 MA) were recruited through Internet and newspaper advertisements. PET data presented here have not been published before.

After receiving a complete explanation of the study, participants gave written, informed consent. Exclusion criteria were: use of psychotropic medications; CNS, cardiovascular, pulmonary, hepatic or systemic disease; HIV seropositivity; pregnancy; lack of English fluency; MRI contraindications; and left-handedness. The Structured Clinical Interview or Mini International Neuropsychiatric Interview for DSM-IV was used to determine Axis-I diagnosis. Any Axis-I diagnosis except nicotine dependence was exclusionary for controls. MA-group participants met criteria for MA dependence and had positive urine toxicology for MA at screening; any current Axis-I diagnosis other than MA dependence or nicotine dependence was exclusionary. All participants were deemed physically healthy, according to medical history and physical examination. Participants were instructed to abstain from MA for ≥ 4 days, from marijuana for ≥ 2 days, and from cigarette smoking for 2 h before each PET scan. Abstinence from recent MA use and negative pregnancy status were determined immediately before each PET and MRI scan by urine tests, and the participants reported the duration of their abstinence. Two control-group subjects and seven MA-group subjects had urine tests positive for tetrahydrocannabinol (THC). Due to the long elimination half-life of THC^[@R18]^, these participants were not excluded. PET and MRI scans were performed on separate days within 3 months of one another.

Demographics and drug-use characteristics {#S4}
-----------------------------------------

Drug use and demographic variables were collected using a survey that queried amount, frequency and duration of MA use, and age of first use. An index of MA exposure was calculated as follows: *average use (grams) × frequency (days/month)/30 × duration (months)*. Information was obtained regarding use of other substances of abuse in the month prior to study, and sleepiness^[@R19]^. Smokers completed the Fagerström Test for Nicotine Dependence (FTND)^[@R20]^.

MA craving was assessed using the Brief Methamphetamine Craving Scale, adapted from the Cocaine Craving Questionnaire-Brief^[@R21]^; with possible scores ranging from 10--70.

Brain scanning {#S5}
--------------

PET data were acquired using a Philips Gemini TF PET-CT, with transverse and axial resolution of 4.8 mm FWHM in the three-dimensional scanning mode. Images were obtained with a 2-mm voxel size (field of view = 128 × 128 × 90). A low-dose CT scan was performed for attenuation correction. Participants were placed in the scanner, in the supine position with the head positioned to avoid movement during scanning. For D1-type receptor scans, emission data were collected for 90 min after a bolus injection of 14.4 ± 1.85 mCi \[^11^C\]NNC112^[@R22]^. D2-type receptor data were collected in two 80-min blocks, with a 20-min intermission, after a bolus injection of 5.0 ± 0.37 mCi \[^18^F\]fallypride^[@R23]^. Data were reconstructed using the row action maximum likelihood (RAMLA) algorithm^[@R24]^ for each 1-min frame.

Structural scans were acquired on a Siemens Sonata 1.5-T scanner for 39 participants (21 control; 18 MA) and a Siemens Trio 3-T scanner for 5 participants (2 control; 3 MA) due to logistical reasons. T1-weighted data, acquired with a magnetization-prepared rapid acquisition with gradient echo (MPRAGE) sequence (TR = 1900 ms, TE = 4.38 ms, flip angle = 15°, field of view = 256 × 256 × 160, 1-mm voxels) were used for co-registration with PET images and definition of volumes-of-interest (VOIs) (see below). Analyses of cortical gray-matter thickness and subcortical volumes (hippocampus, amygdala, globus pallidus, thalamus, and striatum) were performed on data from the Sonata 1.5-T scanner (n = 39).

PET data processing {#S6}
-------------------

Reconstructed \[^11^C\]NNC112-scan data were combined into 23 images, consisting of four 1-min frames, three 2-min frames, and sixteen 5-min frames. The reconstructed data from \[^18^F\]fallypride scans were combined into 16 images, each containing data averaged over 10 min. FSL MCFLIRT (FMRIB Centre, Dept. Clinical Neurology, University of Oxford) was used for motion correction^[@R25]^. The images were then co-registered to the MPRAGE image using a 6-parameter, rigid-body spatial transformation (FSL FLIRT).

VOIs were derived from individual MPRAGE images using FSL FIRST^[@R26]^. Caudate and putamen VOIs were combined to constitute a single striatum VOI. The cerebellum was used as the reference region^[@R27]^. A cerebellum VOI, including the hemispheres but not the vermis, was manually created in standard space (MNI152 template) and transformed into native space with FSL FNIRT.

Time-activity data within VOIs were extracted from PET images and imported into PMOD Kinetic Modeling (PKIN) (PMOD Technologies Ltd., Zurich). The simplified reference tissue model (SRTM)^[@R28]^ was used to calculate BPND with time--activity curves from VOIs as follows: C~T~(t) = R1C~R~(t) + (k2 − R1k2/(1 + BPND))C~R~(t) \*exp(-k2t/(1 + BPND)) where C~T~(t) is the total radioactivity concentration in the striatum VOI measured by PET, R1 is the ratio of K1 to K1′ (K~1~, influx rate constant for the striatum; K1′, influx rate constant for the cerebellum), C~R~(t) is the radioactivity concentration in the reference region (cerebellum), and \* denotes the convolution integral. The parameters R1, k2, and BP~ND~ in this model were estimated by a nonlinear curve-fitting procedure.

Morphological analysis {#S7}
----------------------

FreeSurfer (version 5.3) was used to assess cortical thickness and subcortical volume from MPRAGE images, as described^[@R29]--[@R31]^. The intensity of the images was normalized to remove bias fields, and a hybrid watershed/surface deformation procedure was applied to remove non-brain tissue^[@R32]^. After Talairach transformation, subcortical structures were segmented^[@R33],\ [@R34]^. To generate cortical surfaces, white matter was segmented, and errors in white-matter topology were corrected^[@R35]^. A tessellation was formed along the boundary between gray and white matter. The tessellation on the white-matter surface was grown outward towards the intensity gradient separating gray matter from cerebrospinal fluid. One control and two MA participants were excluded because of inaccurate segmentation. Following demonstration of a significant association between D1-type BPND with the global mean of cortical gray-matter thickness in the MA group, associations of D1-type BPND with thickness in individual cortical regions were tested. Frontal, temporal, occipital, and insular regions were selected for analysis because age-related gray-matter deficits in these regions were reportedly accelerated by MA use^[@R36]^.

Statistical analyses {#S8}
--------------------

Group differences in demographic data were evaluated by Student's *t* or chi-squared tests. ANCOVA was used to evaluate group differences in BPND, cortical gray-matter thickness and subcortical gray-matter volumes. Age, sex and smoking status were included as covariates of no interest because of evidence that they affect dopamine-receptor density^[@R37]--[@R40]^ and brain structure^[@R41]^.

Associations of D1- and D2-type BPND in the caudate/putamen VOI with cortical gray-matter thickness and subcortical volumes were evaluated using partial correlation analysis, controlling for age, sex and smoking status. The nucleus accumbens was not included in this analysis because of evidence that the coding of direct and indirect pathways by D1 and D2 receptors, respectively, is not valid for projections from the nucleus accumbens^[@R42]^. Group differences in correlation were tested using Fisher's *r* to *z* transformation. Associations of gray-matter thickness with cumulative MA use and MA craving were evaluated using partial-correlation analysis controlling for age, sex and smoking status. These analyses were conducted using SPSS IBM 19 (IBM, Armonk, NY) with *p* \< 0.05, two-tailed, as the criterion for significance. Results are shown as mean ± SD.

Results {#S9}
=======

Participant characteristics ([Table 1](#T1){ref-type="table"}) {#S10}
--------------------------------------------------------------

Twenty-three control and 20 MA participants had \[^18^F\]fallypride scans, and 18 control and 19 MA participants had \[^11^C\]NNC112 scans. Brain structure from 20 control and 16 MA participants, who all had \[^18^F\]fallypride scans, and from 15 control and 14 MA participants who had \[^11^C\]NNC112 scans, was analyzed. The groups did not differ in age or sex distribution, but the MA group gave higher sleepiness scores. The MA group included a higher proportion of smokers. Smokers in the groups did not differ on nicotine dependence, smoking history or cigarettes smoked per day. Nine control and 12 MA subjects reported alcohol use in the month before study. Seven control and 12 MA subjects reported marijuana use in the month before study. MA-group participants reported using MA on 24.8 ± 8.08 days in the month before study, first using MA at 22.7 ± 8.40 years of age. Abstinence time from last MA use to scanning was 10.2 ± 6.22 days, 7.2 ± 4.61 days and 8.50 ± 5.03 days for the \[^11^C\]NNC112, \[^18^F\]fallypride and MRI scans, respectively.

D1- and D2-type receptor BPND ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}) {#S11}
-------------------------------------------------------------------------------------------------

The groups did not differ in D1-type BPND in the caudate/putamen \[1.9 ± 0.31 (control), 1.8 ± 0.47 (MA); *F*~1,\ 32~ = 0.050, partial *η*^2^ (*η~p~*^2^) = 0.002, *p* = 0.82\] or in striatal subregions: caudate (*p* = 0.40), putamen (*p* = 0.88), and nucleus accumbens (*p* = 0.27). However, D2-type BPND was lower in the MA group than the control group in the caudate/putamen \[24.0 ± 6.57 VS. 30.6 ± 3.65; *F*~1,\ 38~ = 13.674, *η~p~*^2^ = 0.265, *p* = 0.001\] and striatal subregions: caudate (*p* \< 0.001), putamen (*p* = 0.002), and nucleus accumbens (*p* = 0.002).

Brain structure {#S12}
---------------

There were no group differences in global mean cortical gray-matter thickness \[2.39 ± 0.11 (control), 2.38 ± 0.14 (MA); *F*~1,\ 31~ = 0.001, *η~p~*^2^ \< 0.001, *p* = 0.98\], or in subcortical volumes (hippocampus: *F*~1,\ 31~ = 0.103, *η~p~*^2^ = 0.003, *p* = 0.75; amygdala: *F*~1,\ 31~ = 0.653, *η~p~*^2^ = 0.002, *p* = 0.43; globus pallidus: *F*~1,\ 31~ \< 0.000, *η~p~*^2^ \< 0.000, *p* = 0.99; thalamus: *F*~1,\ 31~ = 3.590, *η~p~*^2^ = 0.10, *p* = 0.07; striatum: *F*~1,\ 31~ = 0.889, *η~p~*^2^ = 0.028, *p* = 0.35).

Association of striatal dopamine receptor BPND with brain structure {#S13}
-------------------------------------------------------------------

D1-type BPND was negatively correlated with global mean cortical gray-matter thickness in MA subjects (*r* = −0.736, *p* = 0.01), but not in controls (*r* = 0.046, *p* = 0.89) ([Figure 2](#F2){ref-type="fig"}). The correlation coefficients differed significantly between groups (*z* = −2.50, *p* = 0.01). D1-type BPND was negatively correlated with gray-matter thickness in temporal (*r* = −0.845, *p* = 0.001) and occipital lobe (*r* = −0.748, *p* = 0.008) \[significant after Bonferroni correction (i.e., *p* \< 0.0125)\], but not in prefrontal (*r* = −0.494, *p* = 0.12) or insular (*r* = −0.034, *p* = 0.92) regions in MA users. D2-type BPND was not correlated with cortical gray-matter thickness in either group (control: *r* = 0.005, *p* = 0.99; MA: *r* = −0.043, *p* = 0.89) ([Figure 2](#F2){ref-type="fig"}).

Among subcortical regions, hippocampal gray-matter volume was negatively associated with D1-type BPND in MA subjects (*r* = −0.790, *p* = 0.004) \[significant after Bonferroni correction (*p* \< 0.01)\]. In addition, trends of negative association between D1-type BPND and gray-matter volume in the thalamus (*r* = −0.715, *p* = 0.013) and striatum (*r* = −0.659, *p* = 0.03) were observed. In controls, D1-type BPND was not significantly associated with hippocampal or other subcortical volumes (*p*'s \> 0.23). The correlation coefficient between D1-type BPND and hippocampal volume showed no group difference (*z* = −1.21, *p* = 0.22). D2-type BPND was not correlated with hippocampal or any subcortical volumes in either group.

Associations of cortical gray-matter thickness with MA use and craving {#S14}
----------------------------------------------------------------------

Global mean cortical gray-matter thickness was negatively associated with cumulative MA use (entire sample: *r* = −0.843, *p* \< 0.001; excluding one outlier: *r* = −0.575, *p* = 0.04). Post-hoc correlation analyses showed that gray-matter thickness was negatively associated with duration (*r* = −0.638, *p* = 0.02), but not amount (*r* = −0.107, *p* = 0.73) or frequency of use (*r* = −0.086, *p* = 0.75). Global cortical gray-matter thickness was also negatively correlated with MA craving (*r* = −0.569, *p* = 0.04) ([Figure 3](#F3){ref-type="fig"}).

In post-hoc analyses, negative associations between cumulative MA use and gray-matter thickness in temporal (*r* = −0.839, *p* \< 0.001) and frontal (*r* = −0.899, *p* \< 0.001) lobes were significant after Bonferroni correction (i.e., *p* \< 0.0125), with a trend in the occipital lobe (*r* = −0.676, *p* = 0.013) but not the insula (*r* = −0.525, *p* = 0.07). MA craving was negatively associated with gray-matter thickness in the temporal lobe (*r* = −0.759, *p* = 0.003), but not in other regions (*p*'s \> 0.06).

Discussion {#S15}
==========

That striatal dopamine D1-type receptor availability, measured *in vivo*, did not differ between MA users and controls, is consistent with postmortem findings in the dorsal striatum but not with the finding of elevated D1-receptor density in the nucleus accumbens^[@R8]^. One postmortem study reported partial desensitization of D1-receptor function in MA users despite unchanged receptor density^[@R43]^. Studies in rodents have produced mixed results, depending on the treatment regimen. Daily administration of 4 mg/kg MA daily for 14 days produced no change in striatal D1-receptor density^[@R44],\ [@R45]^, but five 15-mg/kg doses at 6-h intervals lowered D1-receptor density in the caudate and putamen^[@R46]^. In the human postmortem study showing elevated nucleus accumbens D1-receptor density, recent MA use was confirmed in biological samples, but participants studied here were abstinent for ≥ 4 days. MA may upregulate D1 receptors in the nucleus accumbens acutely, with subsequent reduction over several days of abstinence from MA. As observed here with MA-dependent subjects, cocaine-dependent subjects, abstinent \>14 days, did not differ from controls in D1-type BPND^[@R47]^.

Cigarette smoking, which is common among stimulant users^[@R48]--[@R50]^, can be a confounding factor, and there were more smokers in the MA group than the control group. However, smoking status was controlled statistically, and D1-type BPND did not differ between nonsmokers and smokers in the control group (controlled for age and sex, *p* = 0.926). We also controlled for the contribution of smoking to the group difference in D2-type BPND, which was seen as well in a separate comparison of smokers alone in our sample (14 controls vs. 18 MA users; controlled for age and sex, *p* = 0.002). Lower D2-type BPND in MA users vs. controls demonstrates similarity of our sample with those studied before^[@R6],\ [@R7]^, indicating that negative findings regarding D1-type BPND were not an artifact of sample selection. Recent findings suggest that lower D2-type BPND in cocaine-dependent individuals is associated with sleep disturbance^[@R51]^. Adenosine A2 receptors, predominantly expressed in striatum, co-localize with D2-type receptors on striatal medium spiny neurons^[@R52]^, which form the indirect pathway, but not with D1-type receptors. Enhanced adenosine levels due to sleep deprivation^[@R53]^ may potentiate internalization of D2-type receptors^[@R54]^, leading to reduced D2-type BPND in MA users. Greater self-reported sleepiness in MA users supports this hypothesis. Thus, sleeplessness can contribute to a deficit in D2-type BPND in MA users.

The negative associations of cortical gray-matter thickness with striatal D1-type receptor availability in MA users may reflect adaptation to striatal D1 receptor activation with chronic MA use. Most striatal neurons (≥ 77%) are GABAergic projection neurons^[@R55]^ that transmit signals via the direct and indirect pathways to SNr/GPi^[@R12]^. Striatal dopamine release enhances the activity of D1-expressing direct-pathway neurons but suppresses activity of D2-receptor-expressing indirect-pathway neurons^[@R13]^. Thus, chronic MA-induced striatal dopamine release may affect cortical responses and produce adaptation. That local injection of D1- but not D2-receptor agonists into the striatum increases cortical c-Fos expression in rats^[@R15]^, suggests a greater contribution of striatal D1 than D2 receptors to cortical activity, consistent with an association between striatal D1- but not D2-type receptors and cortical structure.

Although this study replicated a previous report of negative association of global mean cortical gray-matter thickness with cumulative MA use^[@R56]^, there were no group differences in the cortical gray-matter thickness. We previously found no difference in global gray-matter volume between MA users and controls recruited using inclusion/exclusion criteria identical to those reported here^[@R57]^. However, focal abnormalities in cerebral cortical structure have been observed in MA users^[@R58]^. Such group differences may be masked by averaging gray-matter thickness to generate a global mean. In addition, the greater proportion of females in the control group than the MA group included in structural analysis may have influenced a group difference, although age and sex were statistically controlled.

Post-hoc analyses indicated a negative association of gray-matter thickness in the occipital and temporal lobes with striatal D1-type BPND. The temporal lobe is the only region where gray-matter thickness was associated with cumulative MA use and MA craving. In a previous study, temporal cortical gray-matter volume in MA users was smaller than in controls matched for smoking status^[@R59]^. In another, the effect of MA use on age-related loss in gray-matter was substantially greater in the temporal lobe than in other cortical areas^[@R36]^.

This study also found no group difference in hippocampal gray-matter volume despite its negative association with D1-type BPND in the MA group, and no group difference in striatal volume despite previously reported greater volume in the striata of MA users^[@R60],\ [@R61]^. Some previous studies showed smaller hippocampal volumes in MA users than controls^[@R57],\ [@R62]^, but others did not^[@R59],\ [@R63]^. The largest of these studies (44 controls, 61 MA users) had a negative finding. Some previous studies also found no group difference in striatal gray-matter volume^[@R59],\ [@R63]^. These inconsistencies may reflect differences in methods, sample sizes, or duration of abstinence. Although previous studies suggested an effect of abstinence on recovery from cortical gray-matter deficits in stimulant users^[@R59],\ [@R64]^, duration of abstinence was not associated with measures of gray-matter thickness or volume here (Pearson correlation: *p*'s \> 0.3). Finally, the negative association between global mean cortical gray-matter thickness and MA craving was consistent with the finding of negative association between MA craving and gray-matter volume in a distributed set of brain regions including temporal and occipital cortex in an independent sample of MA users^[@R65]^.

This study has limitations, including a modest sample size. For logistical reasons, there were some gaps in time between the self-report, PET, and MRI measures, which ideally would have been collected on the same day, given evidence for effects of abstinence on cortical gray-matter volume^[@R59]^. However, duration of abstinence prior to each scan was not significantly different, and including days abstinent at MRI scanning as a covariate did not change the correlation between D1-type BPND and cortical gray-matter thickness (r = −0.706, p = 0.02). That some of the participants studied had positive urine tests for marijuana even though they endorsed abstinence from marijuana use for at least 2 days before testing is a potential limitation. Indeed, dopaminergic neurons are modulated by the endocannabinoid system ^[@R66]^, and recent reviews indicate effects of both THC and cannabidiol ^[@R67],\ [@R68]^. Most relevant to our manuscript are findings related to striatal dopamine receptors. The findings are inconsistent, with one study finding that acute THC administration decreased dopamine type D1 and D2 receptor Bmax values in rat striatum ^[@R69]^, and another finding no effect ^[@R70]^. In a human PET study, cannabis users did not differ from controls in striatal D2-type receptor BPND ^[@R71]^. Concern regarding effects of possible recent marijuana use by participants in our study is tempered, however, by the observation that THC status, determined by urine toxicology, was not a significant covariate of no interest in the results. Other limitations are associated with the radiotracers. Some affinity of \[^11^C\]NNC112 to 5-HT2A receptors^[@R72]^ precludes definitive statements regarding D1-type receptors, but this nonspecificity should not be problematic for measurements in the striatum, which has a negligible density of 5-HT2A receptors^[@R73]^. \[^18^F\]Fallypride has high affinity for D2-type receptors, but it does not distinguish between D2 and D3 receptor subtypes^[@R74]^.

Finally, causal relationships among biochemical, clinical and brain structural measures cannot be claimed as this is a cross-sectional study. Nonetheless, the results suggest a possible role of striatal dopamine D1-type receptors in MA-induced neuroadaptation in cortical gray-matter structure and, in turn, MA craving. More work is needed to define the link between D1 receptors and effects on cortical gray matter and various clinical aspects of MA-use disorder.
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![Averaged D1- and D2-type receptor BPND maps of participants in control (D1-type: n = 18; D2-type: n = 23) and MA groups (D1-type: n = 19; D2-type: n = 20) (top). No group difference was observed in D1-type BPND in striatum (caudate and putamen collectively) (*F*~1,\ 32~ = 0.050, *p* = 0.82) whereas striatal D2-type BPND differed between groups reflecting a lower mean value for the MA group (*F*~1,\ 38~ = 13.674, *p* = 0.001). In a jittered plot at bottom, blue dots represent subjects in the control group and green dots are those in the MA group.](nihms883217f1){#F1}

![Striatal D1-type receptor BPND is negatively correlated with global mean cortical gray-matter thickness in the MA group. Scatter plots displaying the correlations of the cortical gray-matter thickness with D1- (top) and D2-type (bottom) receptor BPND by group. Correlation coefficients (r) and significance (p) were determined, controlling for age, sex and smoking status.](nihms883217f2){#F2}

![Global mean of cortical gray-matter thickness is negatively associated with cumulative MA use and craving. Correlation coefficients (r) and significance (p) were determined controlling for age, sex and smoking status.](nihms883217f3){#F3}

###### 

Characteristics of Research Participants.

                                                      Control (n = 23)   MA (n = 21)    Group difference
  --------------------------------------------------- ------------------ -------------- -------------------------------
  Age (years)                                         33.2 ± 6.37        36.3 ± 10.74   *t*~42~ = −1.139, *p* = 0.26
  Male/Female                                         11/12              15/6           *χ^2^* = 2.53, *p* = 0.11
  Smoker/Nonsmoker                                    14/9               119/2          *χ^2^* = 5.132, *p* = 0.02
   For smokers:                                                                         
    FTND                                              3.4 ± 2.41         2.8 ± 2.42     *t*~31~ = 0.752, *p* = 0.46
    Pack-years                                        7.6 ± 7.71         6.7 ± 7.81     *t*~31~ = 0.325, *p* = 0.75
    Cigarettes/day                                    11.2 ± 9.82        8.1 ± 6.36     *t*~31~ = 1.123, *p* = 0.27
  Stanford Sleepiness Scale                           1.8 ± 1.20         3.1 ± 1.53     *t*~42~ = −3.297, *p* = 0.002
  Days of alcohol use in past month                   7.8 ± 6.87         6.9 ± 6.22     *t*~19~ = 0.300, *p* = 0.77
  Days of marijuana use in past month                 3.9 ± 3.24         5.2 ± 5.84     *t*~17~ = 0.542, *p* = 0.60
  Days of MA use in past month                        \-                 24.8 ± 8.08    \-
  Age of first MA use (years)                         \-                 22.7 ± 8.40    \-
  Average amount of current MA use per day (grams)    \-                 0.7 ± 0.34     \-
  Duration of MA use at the current amount (months)   \-                 67.6 ± 88.1    \-

Values are shown as mean ± SD. Group differences were evaluated by unpaired Student's *t*-test or chi-squared test.

FTND: Fagerström Test for Nicotine Dependence

###### 

D1- and D2-type receptor availability in striatal subregions.

                                    Control        MA            Group difference
  --------------------------------- -------------- ------------- -------------------------------------------
  D1-type receptor BPND             n = 18         n = 19        
   Caudate                          1.7 ± 0.32     1.7 ± 0.46    4.7%, *F*~1,\ 32~ = 0.732, *p* = 0.40
   Putamen                          2.0 ± 0.32     1.8 ± 0.49    7.1%, *F*~1,\ 32~ = 0.021, *p* = 0.88
   Nucleus accumbens                1.6 ± 0.35     1.4 ± 0.38    15.3%, *F*~1,\ 32~ = 1.282, *p* = 0.27
  PET tracer: \[^11^C\]NNC112                                    
   Injected dose                    14.4 ± 1.80    15.7 ± 2.81   −8.8%, *t*~35~ = −1.614, *p* = 0.12
   Specific activity                5.3 ± 5.85     3.7 ± 4.83    29.3%, *t*~35~ = 0.884, *p* = 0.38
                                                                 
  D2-type receptor BPND             n = 23         n = 20        
   Caudate                          27.2 ± 3.35    21.1 ± 5.72   22.3%, *F*~1,\ 38~ = 15.956, *p* \< 0.001
   Putamen                          32.8 ± 3.94    25.8 ± 7.29   21.3%, *F*~1,\ 38~ = 11.686, *p* = 0.002
   Nucleus accumbens                25.6 ± 3.61    19.6 ± 6.31   23.5%, *F*~1,\ 38~ = 11.389, *p* = 0.002
  PET tracer: \[^18^F\]fallypride                                
   Injected dose                    5.0 ± 0.39     5.0 ± 0.37    −0.7%, *t*~41~ = −0.304, *p* = 0.76
   Specific activity                10.3 ± 11.18   9.7 ± 6.50    5.6%, *t*~41~ = 0.201, *p* = 0.84

Values are shown as mean ± SD. Group differences were evaluated by ANCOVA controlling for age, sex and smoking status.
